$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)GlobeNewsWire • 06/30/25
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to ShareholdersBusiness Wire • 06/27/25
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsGlobeNewsWire • 05/08/25
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 03/29/25
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 02/07/25
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/05/24
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy StudyBenzinga • 08/15/24
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 08/14/24
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerGlobeNewsWire • 08/14/24
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 05/13/24
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care ConferenceGlobeNewsWire • 05/08/24
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 03/21/24
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.GlobeNewsWire • 02/20/24
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewsWire • 11/27/23
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 11/10/23
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/03/23
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. WeberGlobeNewsWire • 10/30/23
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewsWire • 09/28/23
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 09/01/23